255 related articles for article (PubMed ID: 36077262)
1. The Mechanism-Based Inactivation of CYP3A4 by Ritonavir: What Mechanism?
Loos NHC; Beijnen JH; Schinkel AH
Int J Mol Sci; 2022 Aug; 23(17):. PubMed ID: 36077262
[TBL] [Abstract][Full Text] [Related]
2. Characterization of ritonavir-mediated inactivation of cytochrome P450 3A4.
Rock BM; Hengel SM; Rock DA; Wienkers LC; Kunze KL
Mol Pharmacol; 2014 Dec; 86(6):665-74. PubMed ID: 25274602
[TBL] [Abstract][Full Text] [Related]
3. Ritonavir analogues as a probe for deciphering the cytochrome P450 3A4 inhibitory mechanism.
Sevrioukova IF; Poulos TL
Curr Top Med Chem; 2014; 14(11):1348-55. PubMed ID: 24805065
[TBL] [Abstract][Full Text] [Related]
4. The effect of ritonavir on human CYP2B6 catalytic activity: heme modification contributes to the mechanism-based inactivation of CYP2B6 and CYP3A4 by ritonavir.
Lin HL; D'Agostino J; Kenaan C; Calinski D; Hollenberg PF
Drug Metab Dispos; 2013 Oct; 41(10):1813-24. PubMed ID: 23886699
[TBL] [Abstract][Full Text] [Related]
5. Structure and mechanism of the complex between cytochrome P4503A4 and ritonavir.
Sevrioukova IF; Poulos TL
Proc Natl Acad Sci U S A; 2010 Oct; 107(43):18422-7. PubMed ID: 20937904
[TBL] [Abstract][Full Text] [Related]
6. Pyridine-substituted desoxyritonavir is a more potent inhibitor of cytochrome P450 3A4 than ritonavir.
Sevrioukova IF; Poulos TL
J Med Chem; 2013 May; 56(9):3733-41. PubMed ID: 23586711
[TBL] [Abstract][Full Text] [Related]
7. The inhibitory and inducing effects of ritonavir on hepatic and intestinal CYP3A and other drug-handling proteins.
Loos NHC; Beijnen JH; Schinkel AH
Biomed Pharmacother; 2023 Jun; 162():114636. PubMed ID: 37004323
[TBL] [Abstract][Full Text] [Related]
8. Icotinib Induces Mechanism-Based Inactivation of Recombinant Human CYP3A4/5 Possibly via Heme Destruction by Ketene Intermediate.
Sun C; Zhao H; Li W; Jia Y; Yang Y; Peng Y; Zheng J
Drug Metab Dispos; 2021 Oct; 49(10):892-901. PubMed ID: 34312304
[TBL] [Abstract][Full Text] [Related]
9. Interaction of CYP3A4 with Rationally Designed Ritonavir Analogues: Impact of Steric Constraints Imposed on the Heme-Ligating Group and the End-Pyridine Attachment.
Samuels ER; Sevrioukova IF
Int J Mol Sci; 2022 Jun; 23(13):. PubMed ID: 35806297
[TBL] [Abstract][Full Text] [Related]
10. An increase in side-group hydrophobicity largely improves the potency of ritonavir-like inhibitors of CYP3A4.
Samuels ER; Sevrioukova IF
Bioorg Med Chem; 2020 Mar; 28(6):115349. PubMed ID: 32044230
[TBL] [Abstract][Full Text] [Related]
11. Mechanistic Studies of Cytochrome P450 3A4 Time-Dependent Inhibition Using Two Cysteine-Targeting Electrophiles.
Barr JT; Wang Z; Min X; Wienkers HJ; Rock BM; Rock DA; Wienkers LC
Drug Metab Dispos; 2020 Jun; 48(6):508-514. PubMed ID: 32193357
[TBL] [Abstract][Full Text] [Related]
12. Mechanism-based inhibition of cytochrome P450 3A4 by therapeutic drugs.
Zhou S; Yung Chan S; Cher Goh B; Chan E; Duan W; Huang M; McLeod HL
Clin Pharmacokinet; 2005; 44(3):279-304. PubMed ID: 15762770
[TBL] [Abstract][Full Text] [Related]
13. P-glycoprotein and cytochrome P450 3A act together in restricting the oral bioavailability of paclitaxel.
Hendrikx JJ; Lagas JS; Rosing H; Schellens JH; Beijnen JH; Schinkel AH
Int J Cancer; 2013 May; 132(10):2439-47. PubMed ID: 23090875
[TBL] [Abstract][Full Text] [Related]
14. Mechanism-based inactivation of cytochrome P-450-3A4 by mifepristone (RU486).
He K; Woolf TF; Hollenberg PF
J Pharmacol Exp Ther; 1999 Feb; 288(2):791-7. PubMed ID: 9918590
[TBL] [Abstract][Full Text] [Related]
15. Mechanism-based inactivation of CYP3A by HIV protease inhibitors.
Ernest CS; Hall SD; Jones DR
J Pharmacol Exp Ther; 2005 Feb; 312(2):583-91. PubMed ID: 15523003
[TBL] [Abstract][Full Text] [Related]
16. Drugs behave as substrates, inhibitors and inducers of human cytochrome P450 3A4.
Zhou SF
Curr Drug Metab; 2008 May; 9(4):310-22. PubMed ID: 18473749
[TBL] [Abstract][Full Text] [Related]
17. Metabolism of the human immunodeficiency virus protease inhibitors indinavir and ritonavir by human intestinal microsomes and expressed cytochrome P4503A4/3A5: mechanism-based inactivation of cytochrome P4503A by ritonavir.
Koudriakova T; Iatsimirskaia E; Utkin I; Gangl E; Vouros P; Storozhuk E; Orza D; Marinina J; Gerber N
Drug Metab Dispos; 1998 Jun; 26(6):552-61. PubMed ID: 9616191
[TBL] [Abstract][Full Text] [Related]
18. Therapeutic drugs that behave as mechanism-based inhibitors of cytochrome P450 3A4.
Zhou S; Chan E; Lim LY; Boelsterli UA; Li SC; Wang J; Zhang Q; Huang M; Xu A
Curr Drug Metab; 2004 Oct; 5(5):415-42. PubMed ID: 15544435
[TBL] [Abstract][Full Text] [Related]
19. Structure-Based Inhibitor Design for Evaluation of a CYP3A4 Pharmacophore Model.
Kaur P; Chamberlin AR; Poulos TL; Sevrioukova IF
J Med Chem; 2016 May; 59(9):4210-20. PubMed ID: 26371436
[TBL] [Abstract][Full Text] [Related]
20. Clobetasol Propionate Is a Heme-Mediated Selective Inhibitor of Human Cytochrome P450 3A5.
Wright WC; Chenge J; Wang J; Girvan HM; Yang L; Chai SC; Huber AD; Wu J; Oladimeji PO; Munro AW; Chen T
J Med Chem; 2020 Feb; 63(3):1415-1433. PubMed ID: 31965799
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
